UBS Group assumed coverage on shares of ALX Oncology (NASDAQ:ALXO) in a report published on Tuesday, Benzinga reports. The brokerage issued a buy rating and a $96.00 target price on the stock.
ALXO has been the topic of several other reports. Cantor Fitzgerald boosted their price target on ALX Oncology from $64.00 to $103.00 and gave the stock an overweight rating in a research report on Wednesday, January 6th. Piper Sandler lifted their price objective on ALX Oncology from $78.00 to $97.00 and gave the stock an overweight rating in a report on Tuesday, December 15th. Credit Suisse Group lifted their price objective on ALX Oncology from $62.00 to $98.00 and gave the stock an outperform rating in a report on Thursday, February 11th. Finally, HC Wainwright assumed coverage on ALX Oncology in a report on Wednesday, February 10th. They set a buy rating and a $100.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $90.67.
NASDAQ ALXO opened at $60.73 on Tuesday. ALX Oncology has a 1-year low of $28.01 and a 1-year high of $117.45. The business’s 50-day simple moving average is $71.49 and its 200-day simple moving average is $68.97.
In other ALX Oncology news, insider Sophia Randolph sold 7,387 shares of the business’s stock in a transaction on Monday, April 12th. The stock was sold at an average price of $59.43, for a total transaction of $439,009.41. Following the completion of the transaction, the insider now owns 198,234 shares in the company, valued at approximately $11,781,046.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jaume Pons sold 16,700 shares of the business’s stock in a transaction on Monday, March 22nd. The stock was sold at an average price of $68.49, for a total value of $1,143,783.00. Following the transaction, the chief executive officer now owns 568,046 shares of the company’s stock, valued at approximately $38,905,470.54. The disclosure for this sale can be found here. Insiders sold a total of 31,474 shares of company stock valued at $2,131,942 over the last quarter.
Hedge funds have recently made changes to their positions in the business. Pacer Advisors Inc. acquired a new position in ALX Oncology during the 4th quarter worth $38,000. Lindbrook Capital LLC lifted its holdings in shares of ALX Oncology by 366.7% in the fourth quarter. Lindbrook Capital LLC now owns 700 shares of the company’s stock valued at $60,000 after buying an additional 550 shares during the period. Penserra Capital Management LLC acquired a new stake in shares of ALX Oncology in the fourth quarter valued at $73,000. First Mercantile Trust Co. lifted its holdings in shares of ALX Oncology by 101.5% in the fourth quarter. First Mercantile Trust Co. now owns 1,209 shares of the company’s stock valued at $104,000 after buying an additional 609 shares during the period. Finally, Morgan Stanley acquired a new stake in shares of ALX Oncology in the third quarter valued at $72,000. Institutional investors own 73.45% of the company’s stock.
About ALX Oncology
ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma.
Further Reading: Is a Roth IRA right for you?
Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.